Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
5 hedge funds and large institutions have $92K invested in Genocea Biosciences, Inc. in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 36 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
88% less funds holding
Funds holding: 40 → 5 (-35)
97% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 36
100% less capital invested
Capital invested by funds: $42.1M → $92K (-$42M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$13M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$5.02M |
| 3 |
CC
Commodore Capital
New York
|
-$3.85M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.22M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$2.46M |
GNCA Hedge Fund Activity: Q2 2022 in Review
5 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2022, worth a combined $92K — down 100% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of GNCA and 1 opened new positions — a net loss of 35 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Barclays, opening a new position worth an estimated $1. The largest seller was NEA Management Company, exiting entirely with an estimated $13M sold.
- 5 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2022, down from 40 in Q1 2022.
- Funds reported $92K of Genocea Biosciences, Inc. stock for Q2 2022, down 100% quarter-over-quarter.
- 1 fund opened new Genocea Biosciences, Inc. positions in Q2 2022 and 36 closed out, a net change of -35 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2022 was Barclays, an estimated $1 added.
- The largest Genocea Biosciences, Inc. seller in Q2 2022 was NEA Management Company, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2022.